INTRODUCTION
Human testicular germ cell tumours (TGCTs) are increasing in incidence worldwide and account for 1% of all neoplasms in young men (Shanmugalingam et al., 2013) . Identifying factors and mechanisms that alter normal testicular growth may facilitate the development of early, less invasive diagnostics and therapeutics for these cancers. TGCTs were first described in testicular biopsy sections from patients that subsequently developed a testicular malignancy (Skakkebaek et al., 1987; Bergstrom et al., 1996; Shanmugalingam et al., 2013) . These are now thought to have a common origin, the foetal gonocyte (Skakkebaek et al., 1987) , which does not differentiate correctly and instead forms a precursor germ cell neoplasia in situ (GCNIS) cell (Skakkebaek et al., 1987; Berney et al., 2016) . Common features include morphological characteristics (a large nucleus and a prominent cytoplasm) and transcript and protein expression profiles (NANOG, OCT3/4 and AP-2c) Sonne et al., 2009) . These molecular markers are associated with an undifferentiated state, typical for cells retaining stem cell-like features that are usually downregulated as gonocytes transform into spermatogonia when spermatogenesis commences, lending support to the hypothesis that GCNIS cells are derived from these foetal sperm precursors .
TGCTs are divided histologically into seminoma and nonseminoma subtypes (Ulbright, 1993) . Seminoma cells are morphologically similar to foetal gonocytes and GCNIS cells, with immune cell infiltrates frequently present (Klein et al., 2016) . Non-seminomas reflect an earlier stage of embryonic development, often containing various somatic tissues (teratoma) or extra-embryonic derivatives (yolk sac tumours) (Rajpert-De Meyts, 2006) . The mechanisms that underpin GCNIS formation and the subsequent progression into malignancy remain poorly characterized; however, several members of the TGF-b superfamily have been implicated as potential contributors (Dias et al., 2008; Fustino et al., 2011; Young et al., 2011) .
Activin/TGFb signalling is initiated at the cell surface by dimeric ligand binding to type I and type II receptors with intrinsic serine/ threonine kinase activity, resulting in the formation of a heterotetrameric receptor complex (Chang et al., 2002; Shi & Massague, 2003) . The activin receptor subunits ALK2 (type 1), ACTRIIA and ACTRIIB (type 2) have been detected in GCNIS and seminoma cells; these serve as receptors for Nodal, BMPs and activin A, all of which are produced in the normal course of mammalian foetal testis development. The presence of receptors in Sertoli cells indicates these cells also respond to activin/TGFb ligands (Dias et al., 2008) . Immunohistochemical evidence of patient-specific synthesis of activin signalling inhibitors highlighted the likelihood that multiple mechanisms affect activin/TGFb signalling and may promote TGCT formation (Dias et al., 2009) . Although few targets of activin/TGFb signalling in human testicular seminoma cells are known, the KIT transcript is regulated by activin A exposure in hanging drop cultures of primary tumour fragments (Jørgensen et al., 2014) and in the human seminoma-like cell line, TCam-2 (Young et al., 2011) . Dynamic TGF-b superfamily member expression in spermatogenic cells has been documented in rodents (Barakat et al., 2008; Mithraprabhu et al., 2010; Mendis et al., 2011) , including immediately after sex determination and then later during gonocyte re-entry into the cell cycle and as they transform into spermatogonia (reviewed in (Young et al., 2015) ). These findings, which demonstrate TGF-b signalling has the capacity to regulate cell fate decision of early germ cells, are the basis for the hypothesis that dysregulation of this signalling axis may contribute to neoplastic germ cell development.
Chemotactic chemokines can function as directional or growth cues for neoplastic cells, generating a favourable environment for tumour expansion or dissemination. Understanding what determines their bioavailability should enhance our knowledge of how somatic signals influence normal and neoplastic germ cell fate. Analyses of human cell lines have revealed the capacity for chemotactic chemokines to contribute to normal and neoplastic growth. Exposure of TCam-2 cells to CXCL12 significantly enhanced their invasion through a basement membrane (Gilbert et al., 2009; McIver et al., 2013) . A gain-of-function mutation in CCR4 (which encodes a receptor for the CCL17 and CCL22 chemokines to signal) increased homing towards these ligands and promoted the expansion of adult T-cell leukaemia cells (Nakagawa et al., 2014) . Of potential relevance to the foetal testis, CXCL12 regulation and CCL17 regulation by activin/TGF-b have been reported in other systems. CXCL12 increased in immature human dendritic cells exposed to activin A (Salogni et al., 2009) , while CCL17 levels were reduced in human keratinocytes exposed to TGF-b1 (Zheng et al., 2002) .
A common feature of normal testicular development includes tissue remodelling to facilitate the developing niche, mediated by the activation of extracellular proteases. Matrix metalloproteinases (MMPs) have been detected in human foetal testes (6 months old), an interval in which gonocytes typically lay dormant prior to transitioning into spermatogonia. In these samples, MMP2 was detected in gonocytes, while MMP9 labelled Sertoli and interstitial cells (Robinson et al., 2001) . This immunohistochemical analysis of foetal human testes implicated metalloproteinases as candidates that may contribute to normal testicular growth. In other pathologies, such as adenocarcinoma (Shah et al., 2010) and advanced stage endometrial cancer (Aglund et al., 2004) , high levels of MMPs are detected, with this linked to poor disease progression.
In the present study, we aimed to identify the cell types in normal testes that contain these important chemokines and MMPs, initially by looking for changes in their cellular expression profiles during progressive development of testicular neoplasms. Additional evidence of MMP regulation by activin A was also sought using TCam-2 cells to examine MMP2 and MMP9 transcripts, protein and activity levels. The results provide an opportunity to understand how changes in activin signalling activity in the foetus or juvenile may influence the events that underpin formation of testicular germ cell tumours.
METHODS

Clinical samples for histological analyses
Human testicular samples were obtained from 15 men who underwent testicular biopsies during andrological workup for infertility, during vasectomy or vasectomy reversal or during surgery for testicular cancer. All testicular cancer specimens were collected at the Department of Clinical Andrology, Centre for Reproductive Medicine and Andrology at the University of Munster and at the Department of Urology, Paediatric Urology and Andrology at Giessen University Hospital. All patients gave written informed consent to use archival tissue specimens for research purposes, approved by the ethics committee of the Medical Faculty of Justus Liebig University Giessen; Ref. No. 100/07. Testicular samples were immersed in Bouin's fixative immediately after excision, fixed overnight and then embedded into paraffin wax. For immunohistochemistry experiments, 5-lm-thick sections were placed onto poly-L-lysine-coated slides and dried for 30 min at 37°C prior to room temperature storage. Testicular tissue specimens were grouped into the following samples: phenotypically normal spermatogenesis (n = 5, mean age 36, range 31-46 years old), GCNIS (n = 5, mean age 26, range 20-35 years old) and seminoma (n = 5, mean age 47, range 40-63 years old). Human term placenta and human tonsil were used as positive controls based on previously published expression profiles (Sierro et al., 2007; Li et al., 2014) .
Immunohistochemistry and sample analysis
Immunohistochemical experiments were performed at Justus Liebig University, Germany, to detect CXCL12 (R&D Systems, Minneapolis, MN, USA; MAB350-100, mouse monoclonal, 1:50)
32 Andrology, 2019, 7, 31-41 and CCL17 (Santa-Cruz, Dallas, TX, USA, SC-12271, Goat polyclonal, 1:100), and at the Hudson Institute of Medical Research to detect MMP2 (Abcam, Cambridge, UK, ab37150, rabbit polyclonal, 1:400) and MMP9 (Abcam, ab38898, rabbit polyclonal, 1:100) using similar protocols. In brief, paraffin sections were deparaffinized and rehydrated through a graded ethanol series (2 9 5 min histosol, 2 9 5 min 100% ethanol, 1 9 5 min 95%, 1 9 5 min 70% ethanol, deionized water 1 9 5 min). Heatinduced antigen retrieval was then performed by immersing slides in citrate buffer (0.01 M citrate, pH 6) which was then microwaved for 5 min at 800W and then for 5 min at 400W. Slides were left to cool at room temperature (20 min), and then, sections were incubated in 1% BSA diluted in TBST (20 mM Tris, 150 mM NaCl, 1% Tween-20 for CXCL12 and CCL17) or 1% BSA and 5% goat serum diluted in TBS (20 mM Tris, 150 mM NaCl for MMP2 and MMP9) in a humid chamber at room temperature for 30 min. Primary antibodies diluted in TBST (CXCL12 and CCL17) or TBS (MMP2 and MMP) were applied overnight at 4°C. Three washes (3 min each) were performed between incubations at room temperature using either TBST (CXCL12 and CCL17) or TBS (MMP2 and MMP9). Primary antibody binding was detected using biotinylated goat anti-mouse for CXCL12, rabbit anti-goat for CCL17 or goat anti-rabbit for MMP2 and MMP9. All secondary antibodies (DAKO, Santa Clara, CA, USA; diluted 1:500 in their respective diluents) were applied in a humid chamber for 1 h at room temperature. After consecutive washes (3 9 5 min), the Vectastain Elite ABC reagent (Vector Laboratories, Burlingame, CA, USA) was applied according to the manufacturer's instructions. Antibody binding was detected either as a brown precipitate following development with 3, 3-diaminobenzidine tetrahydrochloride (MMP2 and MMP9) or a deep red signal following development with 3-amino-9-ethylcarbazole (CXCL12 and CCL17), with sections counterstained using Harris Haematoxylin. Stained slides were then dehydrated through a graded ethanol series (70% ethanol 3 min, 95% ethanol 3 min, 2 9 100% ethanol 5 min, 2 9 histosol 5 min) and mounted using DPX (Sigma-Aldrich, St. Louis, MO, USA) mounting media. Immunostained sections were scored manually using a brightfield microscope (BX-50, Leica) operating at 910, 920 and 940 objectives. Relative staining intensity, assessed by a single operator and then independently confirmed, was graded as negative when signal matched that of the negative control (À). Subsequent sections were evaluated as containing low (+), moderate (++) or high/strong (+++) immunoreactivity. Images were captured by a Pulinix TMC-6 camera coupled to a computer using a software package, CELLSENS (Olympus, Tokyo, Japan). For each sample, the types of cells stained, the relative intensity of the stain and cellular localization of signal (plasma membrane associated, cytoplasmic, nuclear, interstitial/somatic) were noted.
Sertoli and germ cells were identified based on nuclear morphology (Clermont, 1963) . Controls for non-specific secondary antibody were performed in all experiments by omission of primary antibody, and these consistently yielded no signal within the seminiferous epithelium or in the interstitial space.
Laser-assisted microdissection, RNA extraction and PCR of human testicular material
To examine target gene transcripts in different regions of normal and neoplastic human testes, laser-assisted microdissection PCR was performed as described previously (Fietz et al., 2011) .
Briefly, paraffin-embedded human testicular biopsies underwent microdissection, with areas representing the whole seminiferous epithelium (tubular compartment, TUB) or interstitial compartment (INT) from phenotypically normal or GCNIScontaining tumours, excised. At least 50 tubules and 20 interstitial areas were excised from each patient sample using the PALM MicroBeam system and PALM ROBO Software (Zeiss, Oberkochen, Germany). For seminoma tumour samples, a 25-lm-thick section was collected from each patient sample. Samples were collected from two patients per histological subtype and RNA extracted using the RNeasy FFPE kit (Qiagen, Hilden, Germany) according to the 'Purification of Total RNA from Microdissected FFPE Tissue Sections' protocol. Genomic DNA was removed by DNase treatment (Roche, Basel, Switzerland), and RNA reverse transcribed into cDNA using Roche Superscript III (Roche) according to the manufacturer's instructions.
PCR products were separated on native 2% agarose gels under constant voltage. To confirm the identity of amplified products, bands were purified using QIAquick PCR Purification Kit (Qiagen) and sequenced by SRD (Scientific Research Development, Oberursel, Germany). Custom-made (IDT Technologies) primer pairs were designed using Primer3 (Koressaar & Remm, 2007) . Primer sequences were as follows:
GAGCGAT were used as the reference gene for loading normalization across all samples and experiments and to control for gDNA contamination. Amplification of PCR products CFX96 Cycler (Bio-Rad, Munich, Germany) followed the protocol: 10 min at 21°C, 15 min at 42°C, 5 min at 99°C and 5 min at 5°C.
TCam-2 cell culture and activin A treatment
TCam-2 cells were obtained from stocks originally supplied by Sohei Kitazawa (Division of Molecular Pathology, Ehime University, Japan; described in Young et al., 2011 . Cells were cultured at 37°C in 5% CO2 in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) with 1% penicillin/streptomycin (Gibco, Gaithersburg, MD, USA) and 10% foetal calf serum (FCS; Quantum Scientific, Australia) and passaged at 80-90% confluency. TCam-2 cells (2.0 9 10 5 per well) were seeded into a six-well plate for 24 h and subsequently serum-starved by culture in RPMI 1640 media for a further 24 h. Cells were then incubated with media only (control) or with either 5 ng/mL or 50 ng/mL activin A (R&D Systems) diluted in serum-free media for 24 h. For RNA analyses, cells were washed in sterile PBS; then, 1 mL TRIzol reagent (Thermo Fisher Scientific) was added to each sample well for collection and storage at À80°C until transcript analysis was performed. For protein analyses, TCam-2 cells were seeded into triplicate wells at~4 9 10 5 cells/well of a six-well plate and cultured as above. Supernatant was collected and stored at À80°C until required. Cells were detached using 1 mL Accutase solution (Innovative Cell Technologies, San Diego, CA, USA) per well at 37°C for 5 min. Plates were tapped gently to detach cells, and 1 mL RPMI 1640/10% FCS was added to quench the enzyme. Cells within the suspension were counted then collected by centrifugation at 1000 g (3 min) with three washes in PBS three times. The final pellet was resuspended in 1 mL RPMI 1640 with 10 lL of protease inhibitor cocktail (Sigma-Aldrich) and vortexed before storage at À80°C.
RNA extraction, cDNA synthesis and qRT-PCR RNA was extracted from cultured cells using TRIzol reagent according to the manufacturer's instructions then immediately treated with Ambion DNase-free (Thermo Fisher Scientific) according to the manufacturer's protocol. First-stranded cDNA synthesis was performed on 500 ng of DNase-treated RNA using 100 U SuperScript III enzyme (Invitrogen Life Technologies, Oregon, USA), 10 mM dNTPs (Fisher Biotec, Waltham, MA, USA), 1 lL oligodT (Promega, Madison, WI, USA), 1 lL random primers (Promega), 0.1M dithiothreitol and MilliQ water to a final reaction volume of 20 lL.
Quantitative PCRs (qRT-PCRs) were performed on the Applied Biosystems 7900HT sequence detection machine (ABI, Foster City, CA, USA) in the Monash Health Translational Precinct Genomics Facility using the manufacturer's software. Synthesized cDNAs were diluted 1:10 in MilliQ water. Standard curves were generated using untreated TCam-2 cells as a template at 1:10, 1:40, 1:160, 1:640 and 1:2560 dilutions. All cDNA samples used for standard curve analysis were diluted in MilliQ water. The primer pairs (IDT Technologies) used were as follows: Sandwich ELISA MMP2 and MMP9 protein levels were quantified using separate DuoSet ELISA kits (R&D Systems) that have no known cross-reactivity to other related proteins according to the manufacturer's instructions. Optical density was measured using a microplate reader (Tecan, Infinite. 200 PRO) set to read at 450 nm, with a correction wavelength of 570 nm.
Gelatin zymography
Gelatin zymography was performed as previously described (Toth & Fridman, 2001 ). Activation of gelatinases was assessed in TCam-2 cell supernatants after cells were serum-starved for 24 h and subsequently exposed to activin A (5 ng/mL or 50 ng/ mL diluted in RPMI 1640) for an additional 24 h. Serum-starved cells were also exposed to either 10 lM SB431542, a pan TGF-b superfamily type I receptor inhibitor (Sigma-Aldrich, stock diluted in DMSO, then diluted in serum-free media) or 10 lM SB431542 plus 5 ng/mL activin A (diluted in serum-free media or vehicle control) for 24 h.
In brief, 15 lL of supernatant representative of 1.5 9 10 3 cells was diluted in 49 SDS-PAGE sample buffer under non-reducing conditions and resolved on a 10% SDS-PAGE gel copolymerized with 0.1% (w/v) gelatin (Sigma-Aldrich; porcine skin-derived). Gels were immersed in an incubation buffer containing 0.2 M NaCl 2 and 0.05 M CaCl 2 for 24 h at 37°C then with 0.5% (w/v) Coomassie brilliant blue R250 (Bio-Rad, Hercules, CA, USA) for 1 h at room temperature. Gels were destained at room temperature, and detection using a Chemi-Doc MP system (Bio-Rad) identified gelatinase activity as bands where gelatin had been digested. Sizes were determined by comparison with a prestained PageRuler protein ladder (Thermo Fisher Scientific). Metalloproteinase activity was confirmed by incubating a subset of gels with incubation buffer containing 0.2 M EDTA to chelate essential cations for 24 h at 37°C, with the absence of bands confirming the presence of active MMPs in TCam-2 cell supernatant.
Statistical analysis
To determine responses to growth factors, values from control (no growth factor, serum-free media only) vs. treatment sample were compared. For qRT-PCR analyses, transcript values were normalized to RPLP0 and expressed as fold change over control, with control value set to 1. For ELISA analyses, cells were assayed in triplicates with protein concentration normalized to the number of cells in each well. Data are presented as the mean of 3-5 independent experiments. Unpaired, nonparametric twotailed t-tests were performed using GraphPad Prism TM (San Diego, CA, USA) to determine statistical relevance, with p < 0.05 considered significant.
RESULTS
Transcripts encoding CXCL12 and CCL17 and their signalling moieties are differentially expressed in tubular and interstitial compartments of normal and neoplastic human testes The presence of mRNAs within the compartments of normal and neoplastic human testes was analysed using material picked using laser-assisted microdissection from paraffin-embedded, Bouin's fixed human testicular specimens by non-quantitative reverse transcription PCR. The CXCL12 transcript was detected in tubule and interstitial compartments of both normal adult human testes and in GCNIS and within whole seminoma homogenates (Fig. 1) . The product signal intensity was relatively stronger in the tubule than in the intersititium of normal testis. CCL17 was amplified from the interstitium of normal adult human testes, within the tubular compartment of GCNIS tumours and in whole seminoma homogenates. In contrast, CCL17 was not amplified from the tubule area of normal adult testes or the interstitial area of GCNIS tumours.
CXCR4 is the canonical receptor for CXCL12, and its encoding mRNA was detected in both tubular and interstitial compartments of the normal adult human testis, and in seminoma homogenates. However, in GCNIS tumours, an intense band was amplified from in the tubular samples, and none from the 34 Andrology, 2019, 7, 31-41 interstitial samples, indicating there is compartment-specific expression of this receptor. CXCL12 also signals via the noncanonical receptor, CXCR7, which was detected in all compartments of all three histological subtypes, with no apparent differences in amplicon band intensity. These results reveal the potential for CXCL12 to function in all compartments of the normal and neoplastic human testis using different receptors. CCR4, encoding the receptor for CCL17 and CCL22, was also detected in all compartments of all three histological subtypes, with the exception of the GCNIS interstitium.
CXCL12, CCL17 and MMP2 and MMP9 cellular localization in normal adult human testes
Immunohistochemistry was used to determine protein expression profiles within sections of phenotypically normal adult human testes. All immunohistochemistry data are summarized in Table 1 and described in the sections below. CXCL12 labelled the Sertoli cell cytoplasm, as previously demonstrated (Gilbert et al., 2009 ). CXCL12-positive cells surrounding the seminiferous epithelium, appearing to be peritubular myoid cells, were evident in three out of five samples, and interstitial CXCL12-positive cells were evident in all samples ( Fig. 2A) . CCL17 was not detectable in four out five specimens of normal adult human testes (Fig. 2B) , with only one sample displaying a very faint cytoplasmic Sertoli cell signal ( Fig. 2B') ; no interstitial signal was observed. MMP2 was detected in the cytoplasm of Sertoli and germ cells (Fig. 2C,C' ), and this signal was relatively more intense in the germ cells (spermatogonia, spermatocytes and round spermatids). In addition, some round spermatids exhibited nuclear MMP2 signal, which confirms a previous report (Chen et al., 2011) (Fig. 2C) . Sertoli cells exhibited cytoplasmic MMP9 and spermatogonia both cytoplasmic and nuclear MMP9 (Fig. 2D) . In normal testes, some peritubular myoid cells contained cytoplasmic MMP9. Two out of five patient samples had low MMP9 immunoreactivity in cells within the seminiferous epithelium, accompanied by intense peritubular staining. CCL17 was not detected in normal testes, CXCL12 only labelled somatic cells, while MMP2 and MMP9 labelled both germ and somatic cells. Target antigen recognition by the antibodies used in this study was tested by performing parallel staining of human term placenta or human tonsil samples; these displayed the immunoexpression profiles previously reported (Xu et al., 2002; Li et al., 2014) (Figure S1 ).
In neoplastic testes, chemokines CXCL12 and CCL17 are present in somatic cells, and metalloproteinases MMP2 and MMP9 are present in both germ and somatic cells
In GCNIS-containing tubules, CXCL12 was detected in the Sertoli cell cytoplasm, in cells surrounding the seminiferous epithelium with the appearance of multilayered peritubular myoid cells, and within a subpopulation of interstitial cells (Fig. 3A) ; GCNIS cells contained no signal (Fig. 3A) . In seminoma tumours, three out of five samples contained sporadic CXCL12-positive cells adjacent to seminoma cells (Fig. 3B,B' ), which may correspond to leucocytes, as is common within this tumour subtype (Klein et al., 2016) . Two of the five samples contained a low-level CXCL12 immunoreactivity. The CCL17 signal in GCNIS tumours was moderately intense within the Sertoli cell cytoplasm and stronger towards the basement membrane (Fig. 3C,  C' ); no other cell types contained a CCL17 signal. Robust CCL17 somatic cell signal was evident in all seminoma samples (Fig. 3D,D' ).
GCNIS-containing tubules contained a strong cytoplasmic MMP2 signal in Sertoli cells and in somatic cells within the interstitium (Fig. 3E) . Cells within the multilayered peritubular myoid cell area exhibited no detectable MMP2 Figure 1 Chemokine signalling moiety transcripts are differentially detected in specific compartments of normal and neoplastic human testes. DNA gel showing transcripts and their predicted amplicon size. Material was collected from two individual patients from each histological subtype using laser-assisted microdissection to isolate cells within the tubular (TUB) and interstitial space (INT). A whole 25-lm-thick section of seminoma tumour (Sem) was utilized. CXCL12 was detected in all compartments of all histological subtypes. In contrast, CCL17 was found in the interstitium of normal adult human testes, within the tubular compartment of GCNIS tumours and in whole seminoma homogenates. No signal was detected in the tubule compartment of normal adult human testes or the interstitial area of GCNIS tumours. CXCR4 and CCR4 were found in all compartments of all histological subtypes excluding the intersititium of GCNIS tumours. CXCR7 was detected in all compartments of all histological specimens. GAPDH was used as the reference gene for all samples and experiments, and the amplified signal was comparatively weaker in GCNIS-derived samples. CXCL12 (A, A'), CCL17 (B, B' ), MMP2 (C, C') and MMP9 (D, D') in normal adult human testes (images representative of n = 5). CXCL12 and MMP2 are present in the Sertoli cell cytoplasm (green arrow) and in interstitial cells (black-dashed arrow and Figure S2 ). CXCL12 localized to peritubular myoid cells (brown arrow). No CCL17 signal was detected (B), other than in part of one sample (B'). MMP2 and MMP9 were readily detected in spermatogonia (red arrow) and MMP2 in post-mitotic germ cells (pink arrow, RND = round spermatid, SPC = spermatocyte). MMP9 was observed in peritubular myoid cells (brown arrow). (a-d) represent control samples lacking primary antibody. Scale bar = 20 lm.
36 Andrology, 2019, 7, 31-41 immunoreactivity, although some GCNIS cells contained a cytoplasmic signal. MMP2 signal was also detected in seminoma samples, labelling some seminoma and neighbouring somatic cells (Fig. 3F,F' ). MMP9 immunoreactivity was weak in the GCNIS cytoplasm of three out of five samples (Fig. 3G) . Sertoli cells and endothelial cells lining blood vessels in GCNIS specimens exhibited an intense cytoplasmic MMP9 signal. Additionally, the MMP9 signal was also found to label the cellular membrane of some somatic and seminoma cells in these samples (Fig. 3H,H') . Table 1 represents a summary of all histological observations, with relative signal intensity and localization of signal indicated. Cellular identification of Sertoli cells (Sc) and peritubular myoid cells (PTM) in normal and GCNIS human testis samples is based on well-established morphological characteristics (Clermont, 1963; de Kretser et al., 1975) . During the progression of pre-invasive GCNIS to seminoma, Sertoli and peritubular myoid cells are lost; thus, when assessing seminoma tumour samples, cells that did not exhibit a germ cell-like morphology were documented as somatic (So) cells. Figures S1 and S2 include representative Figure 3 CXCL12 (A, B), CCL17 (C, D), MMP2 (E, F) and MMP9 (G, H) in GCNIS-containing tubules (A, C, E, G) and seminoma tumours (B-H and B'-H') . All four proteins were detected in the Sertoli cell cytoplasm in GCNIS-containing tubules (green arrow). GCNIS cells (black arrows) contained cytoplasmic MMP2 and MMP9 signals. CXCL12 was detected in the peritubular layer (brown arrow) in GCNIS-containing tubules. In seminomas, somatic cells (blackdashed arrows) labelled with CXCL12 (B, B'), CCL17 (D, D'), MMP2 (F, F') and MMP9 (H, H'). MMP2 and MMP9 signals were associated with seminoma cells (blue arrow). Insets show samples lacking primary antibody. Scale bar = 20 lm.
images of two different samples of normal human testes and seminoma samples to illustrate the signal heterogeneity within individual samples and between samples of the same histological subtype.
Activin A elevates MMP2 and MMP9 transcripts and protein levels in TCam-2 cells TGF-b superfamily ligands, including activin A, influence production of MMP2 and MMP9 in cells of the human uterine epithelium (Jones et al., 2006) . In newborn mouse testes, activin A mRNA is at its highest level as gonocytes exit quiescence and re-enter the cell cycle, prior to migration to the basement membrane (Barakat et al., 2008) . Mmp2 activity and Mmp9 activity are also highest in this interval (Guyot et al., 2003) ; thus, to test for a relationship between activin A bioactivity and MMP2 and MMP9 production in human germ cell-like cells, TCam-2 cells were examined following activin A exposure (Fig. 4A-C) . TCam-2 is a seminomaderived cell line that retains characteristics of human seminoma tumours and exhibits gonocyte-like responses to TGFb ligands (de Jong et al., 2008) . TCam-2 cells were exposed to either 5 ng/mL or 50 ng/mL activin A for 24 h and transcripts measured by qRT-PCR. MMP2 and MMP9 were significantly elevated (fourfold and 30-fold) in samples treated with 50 ng/mL activin A after 24 h, relative to control samples (Fig. 4A,B ). MMP2 and MMP9 proteins are secreted as inactive zymogens; therefore, supernatants were collected from TCam-2 cells exposed to activin A for 24 h to assess if these transcripts were translated within this interval (Fig. 4C) . TCam-2 cells treated with 5 ng/mL or 50 ng/mL activin A exhibited significantly elevated total MMP2 levels, increasing to 65 pg/mL (twofold) and 75 pg/mL (threefold), compared to controls (32.5 pg/mL). The concentration of MMP9 in the supernatant of cells exposed to activin A did not differ significantly from control values. These results demonstrate that activin A promotes MMP2 secretion from TCam-2 cells, implicating activin A as a growth factor that potentially modulates MMP2 production within human testicular germ cell tumours.
Activin A elevates MMP2 enzyme activity in TCam-2 cell culture supernatant after 24 h
To investigate whether the activin-induced increase in secretion of total MMP2 was accompanied by changes in enzyme activity, gelatin zymography was performed using supernatant from cells exposed to either activin A or to SB431542 (to block activin A signalling) or to vehicle as controls (Fig. 5) . Exposure of TCam-2 cells to 5 ng/mL or 50 ng/mL activin A for 24 h supported the presence of active MMP2, evidenced by strong bands at 62 kDa, relative to cells exposed to serum-free media. Intense bands at 72 kDa, representing inactive MMP2, were detectable in samples that had been exposed to both doses of activin A. Active MMP9 (82 kDa) and inactive MMP9 (92 kDa) were not detected in any of the three independent experiments performed.
To confirm the capacity for activin A to elevate MMP2 activity in this culture system, parallel experiments were performed in which cells were exposed to a vehicle control, 10 lM SB431542 or 5 ng/mL activin A plus 10 lM SB431542 for 24 h. The lower dose of activin A (5 ng/mL) was selected based on previously documented levels during the onset of murine spermatogenesis (Barakat et al., 2008) . Cells exposed to a cocktail of activin A and SB431542 did not demonstrate high levels of MMP2 activity in the supernatant, as indicated by a lack in observable change in band intensity at 62 kDa (active) or 72 kDa (inactive) compared to vehicle or SB431542-alone treated cells. Collectively, these results implicate activin A as a growth factor that has the capacity to elevate the secretion of active MMP2 from neoplastic human germ cells.
DISCUSSION
The present study details the protein expression profiles of two chemotactic chemokines, CXCL12 and CCL17, and two metalloproteinases, MMP2 and MMP9, in normal and neoplastic human testes. The outcomes from this work highlight potential pathways through which factors that alter activin A bioactivity may influence testicular function. Notably, CCL17 was absent from seminiferous epithelium of the normal testes, but readily (A) (B) (C) Figure 4 Activin A increases MMP mRNA and protein levels in TCam-2 cells. (A&B): MMP2 and MMP9 transcripts were measured 24 h after activin A exposure at the indicated concentrations, with comparisons made relative to control cells exposed to serum-free media only. Both transcripts were significantly higher 24 h after 50 ng/mL activin A exposure (fourfold and 15-fold, respectively). Transcript values for each target in each sample (n = 5) were normalized to RPLP0, averaged, and means graphed. (C) ELISA analysis was performed using supernatant collected from TCam-2 cells exposed to activin A at the indicated doses. MMP2 was secreted into the culture media at higher concentrations than MMP9 under control conditions (30 pg/mL vs. 10 pg/mL). Stimulating TCam-2 cells with 5 ng/mL or 50 ng/mL activin A for 24 h resulted in significant (p < 0.01) twofold and threefold increases in MMP2 secretion, respectively, while MMP9 was unchanged. Each value from the ELISA (n = 5 independent experiments) was normalized to the proportion of cells in that well and expressed as protein concentration (pg) relative to 100,000 cells per mL. p values are calculated using a nonparametric Mann-Whitney U-test, where the asterisk indicates significance: * <0.05, **<0.01, Error bars represent standard deviation.
38 Andrology, 2019, 7, 31-41 detected in the Sertoli cell cytoplasm when GCNIS cells were present. We also provide new evidence of the capacity of activin A to influence the level of MMP2 activity in testicular germ cell tumours. The detection of transcripts encoding CXCL12 and CCL17 and their receptor moieties implicate both ligands as potential contributors to human germ cell development. The absence of detectable transcripts encoding CXCL12 signalling receptors, CXCR4 and CXCR7, and the CCL17 receptor, CCR4, in the interstitial space of GCNIS tumours, suggests Leydig cells, immune cells and fibroblasts within this area may be unresponsive to these ligands. The novel detection of CXCR7 mRNA in all compartments of each histological subtype indicates that CXCL12 signals may be conveyed by this receptor in adult testes.
Previous studies identified CXCL12 in the Sertoli cell cytoplasm in normal adult testes, and it has been shown to act on undifferentiated germ cells which contain the CXCR4 receptor (Gilbert et al., 2009; McIver et al., 2013) . While production of CXCL12 may contribute to normal testicular development, its synthesis in the neoplastic testis may also create a somatic niche permissive for cancer cell maintenance, for example by sustaining neoplastic cells with immature germ cell features. Along with confirming the presence of CXCL12 in human Sertoli cells, we provide new evidence of CXCL12-positive cells within the interstitium of normal and GCNIS-containing testes. Some of these cells have the characteristic appearance of immune cells (Klein et al., 2016) , leading us to propose that CXCL12 may be amongst the chemotactic or cell growth signals derived from immune cells which influence TGCT fate (Defalco et al., 2015) .
Given that testicular germ cell tumours are understood to arise from foetal gonocytes that have evaded normal differentiation cues, it is considered that dysregulation between somatic and germ cells may underpin the formation of GCNIS cells (Sonne et al., 2009) . In adult testes, CCL17 was evident in the Sertoli cell cytoplasm only when GCNIS cells were present. Kliesch and colleagues showed Sertoli cells surrounding GCNIS resemble a pre-pubertal phenotype, with selective re-expression of cytokeratin-18 (Kliesch et al., 1998) . Hence, the detection of CCL17 in GCNIS tumours may also reflect this change in Sertoli cell phenotype to a less mature state. CCL17 was additionally found in some somatic cells in seminoma tumours that most closely resemble a subpopulation of immune cells, and these may be dendritic cells and macrophages, which produce CCL17 in other pathologies (Ait Yahia et al., 2014) .
High levels of MMP2 and MMP9 are found in lung and ovarian carcinomas (Kliesch et al., 1998; Schmalfeldt et al., 2001) , as described here for testicular germ cell tumours. Immunodetection revealed the presence of MMP2 in undifferentiated spermatogonia, spermatocytes and spermatids. The presence of MMP2 in post-mitotic germ cells supports a previous report (Chen et al., 2011) in which the authors hypothesized that germ cell migration towards the lumen prior to spermiation may involve increased MMP levels by means which are yet to be determined. MMPs may contribute to tumour progression, for example when the blood-testis barrier is breached. Our finding of elevated MMP2 and MMP9 levels within Sertoli cells of GCNIS tumours suggests they could mediate the breakdown of the epithelial barrier to permit neoplastic germ cell movement into the intersititium.
The presence of nuclear MMP9 has been documented in several cell types, including human neuroblastoma cells, human endothelial cells (Sinha et al., 2014) , rodent myoblasts (Zimowska et al., 2013) and murine macrophages (Marchant et al., 2014) . The nuclear MMP9 signal in spermatogonia and cells around the seminiferous epithelium, as illustrated in this study, may be associated with processes such as mitosis that require nuclear matrix degradation, a proposal that requires further investigation.
Identifying cellular events that influence somatic cell behaviours may clarify how testicular germ cell tumours form. Activin/TGF-b signalling has the capacity to drive gelatinase production in other reproductive tissues and cancers (Jones et al., 2006) . The ACTRIIA (type 2 receptor) protein has been detected in gonocytes in foetal human testes and in seminoma cells of the adult testis, although it could not be identified in adult germ cells (Anderson et al., 2002) . These results suggest that the abnormal presence of activin signalling moieties in neoplastic germ cells of adult testes influences the progression and/ or proliferation of these tumour cells (Dias et al., 2008) . The present demonstration that activin A stimulates MMP2 and MMP9 synthesis reveals one potential mechanism through which an altered balance of competing TGF-β superfamily ligands may influence TGCTs, with activated MMPs implicated in altering cell signalling in many contexts associated with neoplasia.
Collectively, these findings indicate how human germ cell tumour responsiveness to activin/TGF-b signalling may influence production of chemokines or metalloproteinases, fostering an environment favourable for TGCT maintenance and/or development. This knowledge can provide a basis for understanding how physiological changes that influence TGF-b superfamily signalling may affect both normal and neoplastic germ cell fate. Figure 5 Activin A induces MMP2 activity in TCam-2 cell supernatant. Zymograms from two independent experiments illustrate MMP2 activity after activin A or SB431542 (SB) exposure. At 24 h, both active MMP2 (62 kDa) and inactive (72 kDa) MMP2 were robustly detected in supernatants after activin A exposure at both doses, relative to controls (media only). Exposing cells to a cocktail of 5 ng/mL activin A and 10 lM SB431542 (A+SB) for 24 h did not alter the active or inactive MMP2 signal, relative to DMSO (vehicle) controls or SB431542-alone treated samples. Active (82 kDa) and inactive (92 kDa) MMP9 signals were not detectable.
